Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
Table 4
Respiratory illness (RIH) and RSV-related hospitalization (RSVH) rates and morbidities encountered during hospital stay according to indication.
Prematurity
CLD
HSCHD
Other
value
RIH
RIH rate
4.4%
12.2%
10.3%
10.3%
<0.0005
Length of stay (mean ± SD)
7.9 ± 14.8
9.9 ± 25.0
8.7 ± 10.9
9.8 ± 18.3
0.469
Length of ICU stay (mean ± SD)
1.5 ± 4.8
1.7 ± 6.9
2.3 ± 5.7
2.5 ± 14.7
0.494
Days of intubation (mean ± SD)
0.7 ± 3.0
1.2 ± 6.6
0.9 ± 3.4
1.2 ± 8.9
0.643
Days of respiratory support (mean ± SD)
1.4 ± 4.8
2.4 ± 7.3
1.8 ± 5.2
3.1 ± 14.9
0.117
RSVH
RSVH rate
1.36%
1.64%
2.05%
2.03%
<0.0005
Length of stay (mean ± SD)
7.7 ± 10.3
10.1 ± 11.4
7.2 ± 7.7
7.2 ± 5.8
0.776
Length of ICU stay (mean ± SD)
1.2 ± 2.6
3.1 ± 11.8
2.6 ± 5.0
1.6 ± 4.0
0.346
Days of intubation (mean ± SD)
0.6 ± 2.0
3.1 ± 11.8
1.6 ± 3.3
1.1 ± 3.3
0.180
Days of respiratory support (mean ± SD)
1.2 ± 2.7
3.6 ± 11.7
2.1 ± 4.7
2.1 ± 4.3
0.294
CLD: chronic lung disease; HSCHD: hemodynamically significant congenital heart disease; ICU: intensive care unit.
